文献速递产科母胎医学

孕前父亲健康与健康母亲不良妊娠结局的关联

Association of preconception paternal health and adverse maternal outcomes among healthy mothers.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-04-23

本研究基于IBM Marketscan数据库2009-2016年669256例健康母亲活产回顾性分析,发现孕前父亲代谢综合征或慢性病诊断数与子痫前期(伴/不伴严重特征)、严重孕产妇发病率呈剂量依赖正相关,与胎盘异常无显著关联。提示父源因素可能影响低危健康孕妇的不良结局。

要点

  • 父亲孕前代谢综合征成分≥2个时,健康母亲子痫前期(不伴严重特征)风险增加21%。
  • 父亲孕前代谢综合征成分≥2个时,子痫前期伴严重特征及子痫风险增加19%。
  • 父亲孕前代谢综合征成分≥2个时,严重孕产妇发病率风险增加9%,胎盘异常风险无显著差异。

核心结论

  • 在健康母亲中,孕前父亲健康与子痫前期(伴或不伴严重特征)风险升高显著相关,与严重孕产妇发病率弱相关。
  • 父源因素可能在低产科并发症风险的健康女性不良结局中发挥重要作用。

研究设计与样本

  • 回顾性分析IBM Marketscan研究数据库2009至2016年健康母亲(20-45岁)的活产记录,共669256例。
  • 通过家庭ID将婴儿与配对父母链接,孕前父亲健康以代谢综合征组分诊断数及常见慢性病诊断评估。
  • 排除有代谢综合征组分的女性,采用Cochran-Armitage趋势检验和广义估计方程模型分析。

主要发现

  • 所有不良母体结局与孕前父亲健康恶化(代谢综合征诊断数或慢性病诊断数)均存在显著趋势(P<.001)。
  • 父亲代谢综合征诊断≥2个者,母亲子痫前期不伴严重特征的比值增加21%(95%CI 1.17-1.26)。
  • 父亲代谢综合征诊断≥2个者,母亲子痫前期伴严重特征及子痫的比值增加19%(95%CI 1.09-1.30)。
  • 父亲代谢综合征诊断≥2个者,母亲严重孕产妇发病率的比值增加9%(95%CI 1.002-1.19)。
  • 胎盘异常在两组的比值相似(校正OR 0.96,95%CI 0.89-1.03)。

临床怎么用

  • 对健康孕妇进行产科风险评估时,可考虑纳入父亲孕前代谢健康状况作为参考信息。
  • 父亲存在多个代谢综合征组分时,或许需加强对母亲子痫前期及严重孕产妇发病的监测。

局限性

  • 本研究为回顾性数据库分析,可能存在未测量混杂因素。
  • 父亲健康基于诊断代码评估,可能低估或误分类实际健康状况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal morbidity continues to be an issue of national and global concern. Paternal preconception health may play a significant role in pregnancy outcomes and has received less attention than maternal health. OBJECTIVE: This study aimed to examine the association between preconception paternal health and the risk for adverse maternal outcomes among healthy mothers. STUDY DESIGN: This was a retrospective analysis of live births from 2009 through 2016 to healthy women aged 20 to 45 years recorded in the IBM Marketscan research database. Infants were linked to paired mothers and fathers using family ID. Preconception paternal health was assessed using the number of metabolic syndrome component diagnoses and the most common individual chronic disease diagnoses (hypertension, diabetes mellitus, obesity, hyperlipidemia, chronic obstructive pulmonary disease, cancer, and depression). Women with metabolic syndrome components were excluded to avoid potential confounding of maternal and paternal factors. Adverse maternal outcomes that were assessed included (1) abnormal placentation including placenta accreta spectrum, placenta previa, and placental abruption; (2) preeclampsia with and without severe features including eclampsia; and (3) severe maternal morbidity, identified as any indicator from the Centers for Disease Control and Prevention Index of life-threatening complications at the time of delivery to 6 weeks postpartum. The trend between preconception paternal health and each maternal outcome was determined using the Cochran-Armitage Trend test. The independent association of paternal health with maternal outcomes was also determined using generalized estimating equations models, accounting for some mothers who contributed multiple births during the study period, and by adjusting for maternal age, paternal age, region of birth, year of birth, maternal smoking, and average number of outpatient visits per year. RESULTS: Among 669,256 births to healthy mothers, there was a significant trend between all adverse maternal outcomes and worsening preconception paternal health defined either as the number of metabolic syndrome diagnoses or number of chronic disease diagnoses (P<.001; Cochran-Armitage Trend test). In the generalized estimating equations model, the odds for preeclampsia without severe features increased in a dose-dependent fashion and were 21% higher (95% confidence interval, 1.17-1.26) among women whose partners had ≥2 metabolic syndrome diagnoses than among women whose partners had no metabolic syndrome diagnosis. The odds for preeclampsia with severe features and eclampsia increased in a dose-dependent fashion and were 19% higher (95% confidence interval, 1.09-1.30) among women whose partners had ≥2 metabolic syndrome diagnoses than among women whose partners had no metabolic syndrome diagnosis. The odds for severe maternal morbidity were 9% higher (95% confidence interval, 1.002-1.19) among women whose partners had ≥2 metabolic syndrome diagnoses than among women whose partners had no metabolic syndrome diagnosis. The odds for abnormal placentation were similar between the groups (adjusted odds ratio, 0.96; 95% confidence interval, 0.89-1.03). CONCLUSION: Among healthy mothers, we report that preconception paternal health is significantly associated with increased odds of preeclampsia with and without severe features and weakly associated with increased odds of severe maternal morbidity. These findings suggest that paternally derived factors may play significant roles in the development of adverse maternal outcomes in healthy women with a low a priori risk of obstetrical complications.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Murugappan G, Li S, Leonard SA, et al. Association of preconception paternal health and adverse maternal outcomes among healthy mothers. Am J Obstet Gynecol MFM. 2021. PMID: 33895399. doi:10.1016/j.ajogmf.2021.100384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。